2016-17  Constant Currency(2)	2016-17  Reported(3)	2015-16 Reported	2014-15  Reported	2013-14 Reported	2012-13 Reported
Total Operating Revenue	7,002	6,923	6,115	5,612	5,504	5,100
Sales Revenue	6,688	6,616	5,909	5,459	5,335	4,950
R&D Investment	643	645	614	463	466	427
Profit before Income Tax Expense	1,958	1,690	1,556	1,714	1,604	1,461
Net profit after tax	1,427	1,337	1,242	1,379	1,307	1,211
Net cash inflow from Operating Activities		1,247	1,179	1,364	1,361	1,312
Capital investment		861	566	414	402	450
Return on Invested Capital (%)		24.50%	26.8%(4)	31.70%	31.80%	32.60%
Basic earnings per share ($)		2.937	2.689	2.923	2.701	2.429
Dividend per share ($)		1.36	1.26	1.24	1.13	1.02

(1) For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.915264 per share (at an exchange rate of A$1.2712/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.986328 per share (at an exchange rate of NZ$1.3699/US$1.00).
(2) Constant currency removes the impact of exchange rate movements to facilitate comparability. For further details please refer to the Directors’ Report.
(3) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(4) 2016 figure includes the gain on acquisition of Novartis' global influenza business of US$176.1 million